Cargando…

Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist

Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkoc, Aldin, Stading, Ashley, Wong, Stephanie, Weaver, Tara, Ghisletta, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534192/
https://www.ncbi.nlm.nih.gov/pubmed/36258708
http://dx.doi.org/10.14740/jmc3983
_version_ 1784802487733059584
author Malkoc, Aldin
Stading, Ashley
Wong, Stephanie
Weaver, Tara
Ghisletta, Leslie
author_facet Malkoc, Aldin
Stading, Ashley
Wong, Stephanie
Weaver, Tara
Ghisletta, Leslie
author_sort Malkoc, Aldin
collection PubMed
description Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs, these patients can develop central alveolar hypoventilation (CAH) secondary to disruptions in neuromodulatory respiratory brainstem control and neural signal initiation and integration. Prior studies have primarily focused their attention on treatment of congenital disorders of CAH, and limited research is available on intubated trauma patients who have signs of ventilator dyssynchrony. Current case reports and animal studies have suggested that noradrenergic and specific serotonergic medications are able to target specific neurologic pathways in the respiratory circuit and induce ventilator synchrony. This case series describes the clinical course of TBI patients treated for ventilator dyssynchrony secondary to CAH with a daily scheduled 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. All patients were ultimately extubated and discharged from the hospital.
format Online
Article
Text
id pubmed-9534192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-95341922022-10-17 Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist Malkoc, Aldin Stading, Ashley Wong, Stephanie Weaver, Tara Ghisletta, Leslie J Med Cases Case Report Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs, these patients can develop central alveolar hypoventilation (CAH) secondary to disruptions in neuromodulatory respiratory brainstem control and neural signal initiation and integration. Prior studies have primarily focused their attention on treatment of congenital disorders of CAH, and limited research is available on intubated trauma patients who have signs of ventilator dyssynchrony. Current case reports and animal studies have suggested that noradrenergic and specific serotonergic medications are able to target specific neurologic pathways in the respiratory circuit and induce ventilator synchrony. This case series describes the clinical course of TBI patients treated for ventilator dyssynchrony secondary to CAH with a daily scheduled 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. All patients were ultimately extubated and discharged from the hospital. Elmer Press 2022-09 2022-09-28 /pmc/articles/PMC9534192/ /pubmed/36258708 http://dx.doi.org/10.14740/jmc3983 Text en Copyright 2022, Malkoc et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Malkoc, Aldin
Stading, Ashley
Wong, Stephanie
Weaver, Tara
Ghisletta, Leslie
Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title_full Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title_fullStr Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title_full_unstemmed Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title_short Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist
title_sort novel treatment of ventilator dyssynchrony from central alveolar hypoventilation syndrome utilizing scheduled 5-hydroxytryptamine-3 receptor antagonist
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534192/
https://www.ncbi.nlm.nih.gov/pubmed/36258708
http://dx.doi.org/10.14740/jmc3983
work_keys_str_mv AT malkocaldin noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist
AT stadingashley noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist
AT wongstephanie noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist
AT weavertara noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist
AT ghislettaleslie noveltreatmentofventilatordyssynchronyfromcentralalveolarhypoventilationsyndromeutilizingscheduled5hydroxytryptamine3receptorantagonist